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A PRIMER ON KIDNEY
TRANSPLANTATION:
ANATOMY OF THE SHORTAGE
PHILIP J. COOK*
KIMBERLY D. KRAWIEC**
I
INTRODUCTION
Thousands of Americans die each year for lack of a suitable kidney donor.
In this primer, we provide a quantitative description of the current shortage,
and discuss future trends and possible solutions. We limit our primer to kidneys
because, for reasons detailed in part II, the bulk of the U.S. waiting list and
transplant activity involves kidneys, and because a variety of factors create
opportunities to address the kidney shortage that are not feasible for most other
organs.
The magnitude of the kidney shortage is indicated by the fact that in 2012,
nearly 35,000 patients were added to the transplant waiting list (plus roughly
1
1400 candidates who needed both a kidney and a pancreas), while there were
2
only about 17,300 transplants—a gap of 17,700. Thus, meeting the current need
(not to mention reducing the length of the waiting list) would require more than
doubling the current rate of transplants. Meanwhile, the waiting list continues
3
to grow and currently stands at about 100,000. It would be far longer were it
not for the fact that 5000 people on the waiting list die each year, and thousands
4
of others are removed because they become too sick to receive a transplant.
In this primer, we provide quantitative data and analysis in support of the
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1. Waiting List Additions Age by Listing Year, U.S. DEP’T HEALTH & HUM. SERVS.,
http://optn.transplant.hrsa.gov/latestData/step2.asp? (choose “Waiting List Additions” for category;
choose “Kidney/Pancreas” for organ; select “Candidates”; then follow “Waiting List Additions by
Age” hyperlink) (last updated Feb. 14, 2014).
2. See infra Figure 1 (Number of transplants in 2012 by organ).
3. Data, U.S. DEP’T HEALTH & HUM. SERVS., http://optn.transplant.hrsa.gov/data/ (last updated
Feb. 14, 2014).
4. See infra Figure 3 (Kidney transplants in 2012 by age-group and sex of recipients).
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following principal conclusions:
1. The kidney shortage presents opportunities for life-saving interventions
that are not possible with other types of organs.
2. The annual kidney shortage, as measured by additions to the waiting list,
is currently about 21,000 per year. There are thousands more who would benefit
from a kidney transplant but, given the vagaries of current waiting-list practices,
are not deemed medically qualified.
3. The kidney shortage has grown rapidly and will continue to grow due to
the continuing gap between need and supply.
4. There is not much prospect of increasing the flow of deceased donations,
because most kidneys from potential donors who meet traditional criteria are
already procured.
5. Living kidney donations are almost all directed, usually to family
5
members.
6. Inducements could likely increase living donations—even directed
donations.
Regarding this last point, it should be noted that financial inducements for
donors are currently regulated by federal law. The relevant law, the National
6
Organ Transplant Act (NOTA), enacted by Congress in 1984, prohibits the
7
transfer of any human organ in exchange for “valuable consideration.” (It also
establishes the Organ Procurement Transplantation Network (OPTN) to
8
allocate deceased-donor organs. ) Excluded from the definition of valuable
consideration are the “reasonable payments associated with the removal,
transportation, implantation, processing, preservation, quality control, and
storage of a human organ or the expenses of travel, housing, and lost wages
incurred by the donor of a human organ in connection with the donation of the
9
10
organ.” As modified by the Charlie W. Norwood Living Organ Donation Act,
NOTA now also specifically states that kidney-paired donation—that is, a case
in which two or more patients with willing donors who are not good biological
11
matches arrange a swap—does not involve valuable consideration.
NOTA does not define the phrase “valuable consideration,” and the precise
12
meaning of the term is far from clear. But the statute is generally assumed to

5. A directed kidney donation is a donation by a donor who intends a particular recipient. An
undirected donation is a donation by a donor who donates without a particular recipient in mind.
UNITED NETWORK FOR ORGAN SHARING, LIVING DONATION 3 (2013), available at
http://www.unos.org/docs/Living_Donation.pdf.
6. Pub. L. No. 98-507, 98 Stat. 2339 (1984) (codified as amended at 42 U.S.C. §§ 273–274e (2006
& Supp. IV 2011)).
7. 42 U.S.C. § 274e (2006 & Supp. IV 2011).
8. Id. § 274.
9. Id. § 274e.
10. Charlie W. Norwood Living Organ Donation Act, Pub. L. No. 110-144, 121 Stat. 1813 (2007)
(codified at 42 U.S.C. §§ 273b, 274e (2006 & Supp. IV 2011)).
11. Id.
12. See Kimberly D. Krawiec & Michael A. Rees, Reverse Transplant Tourism, 77 LAW &
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prohibit a wide range of inducements to donate, including monetary payments
to donors that go beyond reimbursement for out-of-pocket expenses. Many
believe, however, that the time is right to reconsider the role of inducements. A
rich array of possible incentive arrangements has been proposed in that regard,
some of which are featured in this issue of Law and Contemporary Problems. In
this primer we do not explore the menu of possibilities, but rather set the table
for the discussion.
In part II we argue that kidneys are unique among the solid organs due to
the combination of the low risk of living donation, the feasibility of extended
waiting times while on dialysis, and Medicare coverage of dialysis and
transplantation for kidney patients. Together these factors motivate the search
for reforms that would increase the flow of living donors. In part III we
demonstrate that kidney transplantation is less expensive and results in better
health outcomes as compared to dialysis, and further explain the health
advantages of living-donor kidneys over deceased-donor kidneys. In part IV we
document the kidney shortage, demonstrating that the current system provides
only about half as many kidneys as are needed for transplantation. The gap
between need and supply was already evident when the data system of the
United Network for Organ Sharing (UNOS) first went online in 1995, and has
steadily widened over the years since then. In part V we discuss the current and
future need for kidney transplantation, finding no reason to predict significant
reductions in new additions to the waiting list. Part VI demonstrates the dim
prospects for increasing kidney-donation rates under the current system:
Donation levels have been static overall since 2006, and donations from living
kidney donors have actually declined from their 2004 peak. Moreover, most
kidneys from suitable deceased donors are already procured—even a perfect
deceased-organ consent-and-allocation system would have yielded only about
5500 kidneys in 2011, not nearly enough to cover the roughly 21,000 kidneys
13
that are needed per year to satisfy unmet demand. In part VII we conclude.
II
KIDNEYS AS A SPECIAL CASE
Kidneys differ from other organs in several important respects. First,
because humans are born with two kidneys but need only one to survive, living
donation is feasible. Although living donation is possible for other organs as
14
well, the donor risks are higher than with kidney donation. In addition,
CONTEMP. PROBS., no. 3, 2014 at 145 (discussing the potential reach of NOTA’s ban on providing
valuable consideration in exchange for transplantable human organs).
13. See infra Table 1 (providing these figures).
14. Living donors can donate one of two kidneys, one of two liver lobes, or part of the lungs,
pancreas, or intestines. Counterintuitively, living donation of a heart sometimes occurs, though the
donor must receive a replacement heart. This may take place if it is determined that someone with
severe lung disease but a healthy heart would have a better health outcome from a combined heart and
lung transplant, rather than simply a lung transplant. U.S. Dept. of Health & Human Servs., Organ and
Tissue
Donation
from
Living
Donors,
ORGANDONOR.GOV,
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extended waiting times for those in need of kidney transplantation are
medically feasible, due to dialysis, and financially feasible, due to Medicare
coverage of end-stage renal disease (ESRD) treatment, which includes dialysis
and kidney transplantation. In contrast, Medicare covers the treatment
(including transplantation) of other organ diseases only if the patient already
15
has Medicare due to age or disability.
Figure 1 indicates that in 2012, 17,286 patients received a kidney transplant,
including 801 who also received a pancreas transplant. Together, these patients
constituted sixty percent of all individuals who received a solid-organ transplant
during that year. Liver transplants were second, with just over twenty percent of
all patients, while heart, lung, and other organs made up the rest.
Medicare coverage of dialysis and transplantation for ESRD obligated the
federal government to pay providers $34 billion in 2011, which amounted to
16
6.3% of total Medicare expenditures. Although ESRD expenditures have been
growing rapidly, so has the overall Medicare budget. As a share of the total,
ESRD expenditures grew from five percent in 1991 to six percent in 1999, and
17
have remained at that level since then.
Behind these figures lies a tale of the ordeals of individuals suffering from
kidney failure. In most cases kidney failure is the culmination of chronic renal
disease, a progressive loss of renal function that extends over months or years,
18
and is usually caused by diabetes, high blood pressure, or glomerulonephritis.
As renal function declines, waste products and excess fluid are excreted at a
slower rate, with a variety of adverse medical consequences and an increasingly
elevated mortality rate, especially from cardiovascular causes. If the disease
progresses all the way to permanent kidney failure (stage five), then dialysis or
19
a kidney transplant is required to sustain life. Typically a dialysis patient
spends several hours at a dialysis center three times per week, although there

http://organdonor.gov/about/livedonation.html (last visited Jan. 29, 2014). Live liver, lung, and heart
donations, however, are each riskier for the donor than is live kidney donation. Q&A on Living
Donation, NAT’L KIDNEY FOUND., http://www.kidney.org/transplantation/livingdonors/infoqa.cfm (last
visited Jan. 29, 2014).
15. See United Network for Organ Sharing, Financing a Transplant: Funding Sources,
TRANSPLANT
LIVING,
http://www.transplantliving.org/before-the-transplant/financing-atransplant/funding-sources/ (last visited Jan. 29, 2014) [hereinafter United Network for Organ Sharing,
Financing a Transplant: Funding Sources].
16. NAT’L. INST. OF HEALTH, 2 2013 USRDS ANNUAL DATA REPORT: ATLAS OF END-STAGE
RENAL DISEASE IN THE UNITED STATES 328 (2013) [hereinafter NAT’L. INST. OF HEALTH, 2 USRDS
REPORT], available at http://www.usrds.org/2013/pdf/v2_ch11_13.pdf.
17. See id. at 328 fig.11.2.
18. Chronic Kidney Disease, WIKIPEDIA, http://en.wikipedia.org/wiki/Chronic_kidney_disease
(last modified Mar. 4, 2014, 11:20 PM); see also Anton C. Schoolwert et al., Chronic Kidney Disease: A
Public Problem That Needs a Public Health Action Plan, PREVENTING CHRONIC DISEASE, Apr. 2006,
at 1, available at http://www.cdc.gov/pcd/issues/2006/apr/05_0105.htm (describing the burdens of chronic
kidney disease).
19. See Executive Summary to KDOQI Clinical Practice Guidelines for Chronic Kidney Disease,
NAT’L KIDNEY FOUND. tbl.3 (2002), http://www.kidney.org/professionals/KDOQI/guidelines_ckd/
p1_exec.htm.
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are at-home alternatives. Dialysis can be compatible with a somewhat normal
life, but the process imposes rigid structure, and is associated with a variety of
20
medical side effects. For those who are healthy enough to endure the rigors of
transplantation, a new kidney provides the hope of a better quality of life, as
21
well as longer life expectancy, as detailed below in part III.
ESRD patients lucky enough to have a relative or friend who are willing to
donate a kidney to them, and who are a close enough biological match, can
22
proceed to transplantation directly, as do about 3000 patients per year. But
23
most of the 115,000 new ESRD patients each year are put on dialysis and at
some point may be screened for entry onto the waiting list for a kidney from a
24
deceased donor. After extensive testing, patients who are deemed healthy
enough to be candidates for transplantation are registered on one or more
25
regional waiting lists. If a patient remains relatively healthy and stays on the
active waiting list, the wait for a kidney from a deceased donor currently
averages over four years, differing widely by region of the country, blood type,
26
and other factors. Those patients who do receive a transplant (from either a
living or deceased donor) can expect their lives to be improved but still
27
difficult. They must take immunosuppressive drugs, which impair their
immune system, and they are nonetheless at risk of graft failure. The “half-life”
of a kidney graft for surviving patients is about thirteen years if from a living
28
donor, and nine years if from a deceased donor. After a transplanted kidney
stops functioning (due to graft failure or other reasons), the patient is placed
back on dialysis, and perhaps back on the waiting list. About fourteen percent
of patients on the UNOS waiting list have undergone a previous kidney
29
transplant. As a group, their waiting time tends to be still longer than for first20. See, e.g., DANIEL OFFER ET AL., DIALYSIS WITHOUT FEAR 3–28 (2007) (discussing the
realities of life on dialysis).
21. See infra text accompanying notes 35–39 (discussing the advantages of transplantation over
dialysis).
22. NAT’L.
INST.
OF
HEALTH,
2013
ADR
REFERENCE
TABLES
§
D.1
http://www.usrds.org/2013/ref/D_modalities_13.xls (select tab “D.1”) (last visited Feb. 20, 2014)
[hereinafter NAT’L. INST. OF HEALTH, 2013 ADR REFERENCE TABLES] (reporting number of patients
starting with a transplant each year).
23. Id.
24. See Gabriel Danovitch, The Kidney Transplant Waiting List, UPTODATE,
http://www.uptodate.com/contents/the-kidney-transplant-waiting-list (last updated Nov. 13, 2013). This
waiting list is kept in the United States by UNOS.
25. UNITED NETWORK FOR ORGAN SHARING, QUESTIONS & ANSWERS FOR TRANSPLANT
CANDIDATES ABOUT MULTIPLE LISTING AND WAITING TIME TRANSFER 2 (n.d.), available at
https://www.unos.org/docs/Multiple_Listing.pdf.
26. See U.S. DEPT. OF HEALTH & HUMAN SERVS., UNITED STATES ORGAN TRANSPLANTATION:
OPTN & SRTR ANNUAL DATA REPORT 2011, at 19 figs.KI 1.10 & KI 1.11 (2012) [hereinafter U.S.
DEPT. OF HEALTH & HUMAN SERVS., OPTN & SRTR REPORT].
27. See generally Benjamin Hippen, The Case for Kidney Markets, NEW ATLANTIS: J. TECH. &
SOC’Y, Fall 2006, at 47.
28. U.S. DEPT. OF HEALTH & HUMAN SERVS., OPTN & SRTR REPORT, supra note 26, at 34
fig.KI 6.7.
29. See Organ by Previous Transplant, U.S. DEP’T HEALTH & HUM. SERVS.,
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timers because in the process of rejecting their first kidney, they formed
antihuman antibodies that make it harder to find compatible future kidney
30
donors.
31

Figure 1: Number of Transplants in 2012 by Organ

http://optn.transplant.hrsa.gov/latestData/step2.asp? (choose “Waiting List” for category; select
“Candidates”; then follow “Organ by Previous Transplant” hyperlink) (last updated Feb. 14, 2014).
30. See Katy Trebern-Launay et al., Poor Long-Term Outcome in Second Kidney Transplantation:
A Delayed Event, PLOS ONE, Oct. 2012, at 1, 2.
31. See Transplants by Donor Type, U.S. DEP’T HEALTH & HUMAN SERVS.,
http://optn.transplant.hrsa.gov/latestData/step2.asp? (choose “Transplant” for category; choose “All”
for organ; follow “Transplants by Donor Type” hyperlink; then select “Organ” under “Add Field to
Report”) (last updated Feb. 14, 2014).
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III
THE CASE FOR LIVING DONATION
That living kidney donation is available at relatively little risk to the donor
suggests there are opportunities to expand the kidney-donor pool that may not
be available for other solid organs. As will be shown in part VI, the prospects
for increasing the number of deceased-donor kidneys are limited, meaning that,
barring major medical breakthroughs, any significant progress in closing the gap
between kidney supply and need will have to come from living donations.
To be sure, living kidney donation is not risk free. The risk of death within
ninety days of surgery is 3.1 per 10,000 donors, as compared to 0.4 per 10,000 in
32
a matched nondonor cohort. To put this statistic into perspective, the reported
surgical-mortality rate for laparoscopic cholecystectomy (gall-bladder surgery)
33
is about 18 per 10,000 surgeries. Importantly, studies find no long-term
34
increased risk of mortality among kidney donors.
These relatively low donor risks must be compared to the benefits of living
kidney donation to recipients and to Medicare ESRD expenditures. First,
kidney transplantation costs less than dialysis. To illustrate, data from the
United States Renal Data System (USRDS) indicates that the per person per
year Medicare costs of ESRD in 2011 (the last year for which data are reported)
were $88,000 for hemodialysis, $72,000 for peritoneal dialysis, and $33,000 for
35
transplantation (including immunosuppression). More importantly, a greater
supply of donors would extend ESRD patient lives and improve their health,
and this is especially true of living-donor kidneys, which last longer than
deceased-donor kidneys.
The average life expectancy for a patient on dialysis is about five years.
Dialysis can cause a variety of serious health complications, including anemia,
36
bone disease, high blood pressure, heart disease, nerve damage, and infection.
37
A kidney transplant extends life expectancy. Transplanted patients also report

32. Dorry L. Segev et al., Perioperative Mortality and Long-Term Survival Following Live Kidney
Donation, 303 JAMA 959, 962 tbl.2 (2010).
33. Id. at 962. Two studies published as this article went to press suggest that the long-term risks of
kidney donation—although still low—are higher for some donors than suggested by previous studies.
Changes in the screening and eligibility of donors may reduce these risks. See Geir Mjøen et al., LongTerm Risks for Kidney Donors, 86 KIDNEY INTERNATIONAL 162 (2014); Abimereki D. Muzaale et al.,
311 Risk of End-Stage Renal Disease Following Live Kidney Donation 579 (2014).
34. Id. at 963.
35. NAT’L. INST. OF HEALTH, 2 USRDS REPORT, supra note 16, at 328. It should be noted that
the bulk of the cost for transplant occurs in the first year, and includes the cost of the organ
procurement, surgery, and in-hospital care. After the first year, the bulk of the costs of maintaining a
transplant are the cost of immunosuppressive medications. The annual $33,000 figure for transplant is
an average over the first several years. See id. at 446.
36. The Benefits of Transplant Versus Dialysis, BETH ISRAEL DEACONESS MED. CTR.,
http://www.bidmc.org/Centers-and-Departments/Departments/Transplant-Institute/Kidney/TheBenefits-of-Transplant-versus-Dialysis.aspx (last visited Jan 29, 2014).
37. Robert A. Wolfe et al., Comparison of Mortality in All Patients on Dialysis, Patients on
Dialysis Awaiting Transplantation, and Recipients of a First Cadaveric Transplant, 341 NEW ENG. J.
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a higher quality of life on several measures, as compared to dialysis patients,
38
and are more likely to return to work than are dialysis patients. Moreover,
living-donor kidneys function longer than deceased-donor kidneys: about
twelve to twenty years on average, as compared to eight to twelve years for
39
deceased-donor kidneys.
A greater supply of donors would also decrease waiting times, producing
additional health benefits. Because of long wait times, most patients do not
40
receive transplants until they have been on dialysis for several years. However,
time spent on dialysis can negatively affect a patient’s health even after
transplantation, in part due to the long-term health problems caused by dialysis.
Research shows that patients who spend two years on dialysis while waiting for
a kidney transplant are three times more likely to lose the transplanted kidney
41
than are those who wait on dialysis for six months or less. Best of all would be
for patients to proceed directly to transplant following renal failure, but just
2.5% of new ESRD patients are transplanted before spending some time on
42
dialysis. One reason is that kidney-related Medicare coverage does not start
until the patient is on dialysis, so that even patients who have a willing,
43
compatible donor may not be able to afford the pretransplant medical workup.
A recent study attempted to assess the overall effects of increasing the
44
number of living kidney donations. The thought experiment was to offer a
reward to living donors. If the offered payment increased living donations
without decreasing deceased donations, the result would be to increase the
transplant rate overall, reduce the wait time for a deceased-donor kidney, and
of course increase the number of recipients who had the benefit of a kidney
from a living donor. The authors estimated that if the rate of living donations
MED. 1725, 1725 (1999); The Benefits of Transplant Versus Dialysis, supra note 36.
38. The Benefits of Transplant Versus Dialysis, supra note 36.
39. Id. USRDS reports,
Among patients who received a deceased donor kidney transplant in 2010, the probability of
all-cause graft failure in the first year following transplant was 0.09, compared to 0.03 in those
receiving a transplant from a living donor. The one-year graft and survival advantage
experienced by living donor transplant recipients continues at five and ten years posttransplant, with [kidney failure] probabilities of 0.15 and 0.38 compared to 0.29 and 0.54 in
those receiving a deceased donor transplant.
NAT’L. INST. OF HEALTH, 2 USRDS REPORT, supra note 16, at 289.
40. Organ Procurement and Transplantation Network Kidney Kaplan-Meier Median Waiting Times
for
Registrations
Listed:
1999–2004,
U.S.
DEP’T
HEALTH
&
HUM.
SERVS.,
http://optn.transplant.hrsa.gov/latestData/step2.asp? (choose “Median Waiting Time” for category;
choose “Kidney” for organ; then follow “Waiting Time by Blood Type” hyperlink) (last updated Feb.
14, 2014) (listing median wait times of between 597 and 2030 days, depending on blood type).
41. Herwig-Ulf Meier-Kriesche & Bruce Kaplan, Waiting Time on Dialysis as the Strongest
Modifiable Risk Factor for Renal Transplant Outcomes, 74 TRANSPLANTATION 1377, 1377 (2002).
42. Michael Abecassis et al., Kidney Transplantation as Primary Therapy for End-Stage Renal
Disease, 3 CLINICAL J. AM. SOC’Y NEPHROLOGY 471, 471 (2008).
43. See United Network for Organ Sharing, Financing a Transplant: Funding Sources, supra note
15.
44. See Lianne Barnieh et al., The Cost-Effectiveness of Using Payment to Increase Living Donor
Kidneys for Transplantation, 8 CLINICAL J. AM. SOC’Y NEPHROLOGY 2165 (2013).
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increased five percent in response to the reward, the result would be an increase
of 0.11 quality-adjusted life years (QALYs) per person on the waiting list; if the
rate of live donations increased twenty percent, the increase would be 0.39
45
QALYs per person.
In sum, dialysis is expensive and results in poor health outcomes for
patients, with average life expectancy on dialysis being only five years. A
successful transplant for a medically eligible patient is likely to improve health.
The chance of success is greater if the transplant occurs soon after renal failure
is established, and no matter when the transplant occurs, kidney transplants
from living donors tend to yield better results than those from deceased donors.
An increase in the number of living kidney donors could thus improve health
outcomes for those with ESRD while reducing the annual cost per patient.
IV
DOCUMENTING THE KIDNEY SHORTAGE
As of November 2013, there were 99,000 candidates on the waiting list for a
kidney transplant, and an additional 2000 waiting for a combination of kidney
46
and pancreas. The waiting list has increased linearly from about 30,000 in 1995
47
(the first year for which online data are available from UNOS). This growth is
the inevitable result of the flow of additions to the list exceeding the flow of
removals throughout this period.
About one-third of those on the waiting list at any one time are inactive,
48
meaning they are not available for an immediate transplant. Most with inactive
status are too sick to tolerate a transplant, or have not completed the medical
workup for a transplant. Other reasons for being inactive include cases in which
the patient chooses to postpone the transplant, is obese, or, in a few cases, is
49
deemed too well. So long as they remain on the waiting list, however, those
with inactive status still accumulate seniority and gain priority for receiving a
transplant when a suitable kidney becomes available.
Table 1 documents the flows on and off the kidney waiting list for a single
year, 2011. That year began with 85,082 on the waiting list, and during the
course of twelve months increased by 2753 candidates. That increase was the
difference between 29,040 net new additions to the list (ESRD patients who
were deemed medically qualified for a transplant and remained on the list at the
end of the year) and 26,287 patients who were removed during the course of the
year. A majority of removals—16,089—were the result of transplants, but 5155
of those who were on the waiting list died, and others became too sick to be

45. Id. at 2165.
46. Data, supra note 3.
47. See infra Figure 2.
48. See U.S. DEPT. OF HEALTH & HUMAN SERVS., OPTN & SRTR REPORT, supra note 26, at 16
fig.KI 1.1.
49. See id. at 16 fig.KI 1.3.
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50

transplanted.

51

Table 1: Accounting for flows on and off the kidney waiting list, 2011
Candidates waiting on January 1, 2011

85,082

Candidates added during 2011
Candidates removed during 2011

29,040
26,287

Transplant
Died
Too sick
Other removal
Candidates waiting on December 31, 2011

16,089
5155
1904
3139
87,835

One reason that the waiting list has been growing is that patients with
52
ESRD have been living longer even in the absence of a transplant. The
growing pool of successful transplants also represents a source of demand
because transplants generally fail within about ten years. Currently fourteen
percent of the waiting list consists of patients who have previously received a
53
kidney transplant.
Although the net increase to the kidney waiting list over the course of 2011
was 2753, that number is not a good measure of the gap between need and
supply because, as noted above, it fails to account for those who die or become
too sick for a transplant while on the waiting list. In order for need to be in
equilibrium with the supply of kidneys for donation, there would have to be
enough kidneys available to accommodate all new additions to the waiting list.
In the ideal situation, all medically eligible patients would have a suitable
transplant organ available within a few months instead of several years, as
under the current regime. The result would be that few eligible patients would
be lost to medical deterioration and death while on dialysis, and most all of
50. It should be noted that some patients are both added and then removed over the course of the
year, and so they show up under both categories. Another way to do the accounting is to track all
patients for one year who are on the waiting list as of January 1 of that year. For example, of the
patients on the waiting list as of January 1, 2012, 14.5% received transplants over the course of the year,
74.6% were still on the waiting list at the end of the year, 5.1% died before receiving a transplant, and
5.2% were removed for various other reasons. E-mail from Sarah Taranto, UNOS Research Dept., to
author Kimberly D. Krawiec (Oct. 28, 2013) (on file with author).
51. U.S. DEPT. OF HEALTH & HUMAN SERVS., OPTN & SRTR REPORT, supra note 26, at 18
tbl.KI 1.8, 37 tbl.KI 8.5. The statistics in this table combine the data for adult and pediatric cases.
Patients who are listed, receive transplants, and then are relisted during the course of 2011 are counted
more than once.
52. See U.S. DEPT. OF HEALTH & HUMAN SERVS., OPTN & SRTR REPORT, supra note 26, at 20
fig.KI 1.14.
53. See Organ by Previous Transplant, U.S. DEP’T HEALTH & HUM. SERVS.,
http://optn.transplant.hrsa.gov/latestData/step2.asp? (choose “Waiting List” for category; select
“Candidates”; then follow “Organ by Previous Transplant” hyperlink) (last updated Feb. 14, 2014).

1_COOK_KRAWIEC_FIG7UPDATE_FINAL (DO NOT DELETE)

No. 3 2014]

A PRIMER ON KIDNEY TRANSPLANTATION

11/11/2014 3:59 PM

11

them would actually receive a transplant. In that sense the need for kidneys for
transplantation is equal to the flow of new additions to the waiting list, or
roughly 35,000 per year at current rates, plus the 3000 or so who are
54
transplanted before being put on the waiting list. By that definition, there are
currently fewer than half as many kidneys for transplantation as needed, as
illustrated by figure 2. In other words, the unmet need is on the order of 21,000
55
kidneys per year. The true number may be far higher, as we discuss in the next
part.
56
Figure 2 provides a historical account of this gap between need and supply.
That gap appeared when the UNOS data system first went online in 1995, and
has widened in subsequent years. Between 1995 and 2006, flows (including both
new additions and transplants) increased steadily, with the need increasing
faster than the supply of kidneys available for transplantation. Since 2006 the
need has continued to increase each year (albeit more slowly), but the rate of
transplants has plateaued.

54. See NAT’L. INST. OF HEALTH, 2013 ADR REFERENCE TABLES § D.1, supra note 22 (roughly
3000 patients received transplants without going on waiting list); infra Figure 2 (Kidney waiting list
additions and kidney transplants per year, 1995–2012).
55. In 2012, there were 16,485 transplants and 34,834 additions to the transplant waiting list.
Others would have been added to the waiting list except that they received transplants before going on
dialysis—the most recent count available is 2855 in 2011. So the relevant comparison is the number of
cases newly qualified for a transplant (34,834 plus 2855) with the actual number of transplants (16,485).
The difference is 21,204. See NAT’L. INST. OF HEALTH, 2013 ADR REFERENCE TABLES § D.1, supra
note 22 (roughly 3000 patients received transplants without going on waiting list); supra Figure 1
(Number of Transplants in 2012 by Organ); infra Table 2 (Kidney waiting list additions by diagnosis,
1995 and 2012).
56. In fact the gap is even wider than depicted, because as noted above some of the transplants
have gone to patients who were never on the waiting list.
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Figure 2. Kidney waiting list additions and kidney transplants per year, 1995–
57
2012
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V
RECIPIENTS: THE CURRENT AND FUTURE NEED FOR KIDNEYS
Figure 3 shows kidney transplants in 2012 by age-group and sex of the
recipient. The number of transplants increases with age, up to around age sixtyfive, with a drop-off thereafter. In every age-group, more men than women
receive transplants. Not shown in this diagram is the breakdown by race:
African American patients receive about one-quarter of all kidney transplants,
58
despite constituting approximately one-eighth the U.S. population. Yet
because ESRD is three-and-a-half to five times as common among black
59
patients than white patients, the likelihood of transplant for black ESRD
60
patients is lower than for white ESRD patients.

57. Kidney Transplants by Donor Type, U.S. DEP’T HEALTH & HUMAN SERVS.,
http://optn.transplant.hrsa.gov/latestData/step2.asp? (choose “Transplant” for category; select
“Kidney”; follow “Transplants by Donor Type” hyperlink; then use “All Donor Types”) (last updated
Feb. 14, 2014); Kidney Waiting List Additions by Donor Type, U.S. DEP’T HEALTH & HUMAN SERVS.,
http://optn.transplant.hrsa.gov/latestData/step2.asp? (choose “Waiting List Additions” for category;
select “Kidney”; follow “Transplants by Donor Type” hyperlink; then use “All Donor Types”) (last
updated Feb. 14, 2014).
58. See Transplants in the U.S. by Recipient Ethnicity, U.S. DEP’T HEALTH & HUM. SERVS.,
http://optn.transplant.hrsa.gov/latestData/step2.asp? (choose “Transplant” for category; choose
“Kidney” for organ; then follow “Transplants by Recipient Ethnicity” hyperlink) (last updated Feb. 14,
2014).
59. Winfred W. Williams & Martin R. Pollak, Health Disparities in Kidney Disease—Emerging
Data from the Human Genome, 369 NEW ENG. J. MED. 2260, 2260 (2013).
60. Jagbir Gill et al., The Effect of Race and Income on Living Kidney Donation in the United
States, 24 J. AM. SOC’Y NEPHROLOGY 1872, 1876 (2013) (“African Americans have [] 46% lower odds
of living donor transplantation.”).
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Figure 3: Kidney transplants in 2012 by age-group and sex of recipient
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Table 2 and figure 4 show the medical conditions leading to entry onto the
waiting list in 1995 and 2012. Diabetes accounts for a large share of new
entrants to the waiting list, growing from 27% of new entrants in 1995 to 32% in
2012. Hypertension follows, accounting for 21% of new entrants in 2012 (up
from 17% in 1995). The remaining entrants suffer from a variety of medical
conditions, including polycystic kidney disease, focal glomerular sclerosis, and
IgA nephropathy. Table 2 also shows the growth in annual additions to the
waiting list, from 17,258 in 1995 to 34,834 in 2012. The number of new entrants
with diabetes and hypertension each more than doubled between 1995 and
2012.

61. Kidney Transplants by Age and Gender, U.S. DEP’T HEALTH & HUMAN SERVS.,
http://optn.transplant.hrsa.gov/latestData/step2.asp? (choose “Transplant” for category; select
“Kidney”; follow “Transplants by Recipient’s Age” hyperlink; choose “Add Field to Report”; and then
click “gender”) (last updated Feb. 14, 2014).
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Figure 4:: Medical con
nditions lead
ding to entry onto the waiiting list

62

63

Table 2: Kidney waitting list addittions by diaggnosis, 1995 aand 2012

Hype
ertension
Diabetes
Other
O

Total
T

1995
3012
17%
4593
27%
9653
56%

2012
7336
21%
11,201
32%
16,297
47%

17,258
100%

34,834
100%

62. See in
nfra Table 2. Hypertension includes hyperrtensive nephro
osclerosis and malignant
hypertension. Diabetes
D
includ
des both type I and type II d
diabetes. The to
op three diagno
oses in the
“other” categorry are polycysticc kidney disease,, focal glomerulaar sclerosis, and
d IgA nephropatthy.
63. Waiting
g List Addition
ns Listing Year by Diagnosis, U
U.S. DEP’T HEA
ALTH & HUMA
AN SERVS.,
http://optn.transplant.hrsa.gov/latestData/step2
2.asp? (choose “Waiting List Additions” forr category,
ey” for organ, select “Candid
dates”; follow ““Waiting List Additions by D
Diagnosis”
choose “Kidne
hyperlink) (lastt updated Feb. 14, 2014). “Hyp
pertension” inclludes both hypeertensive nephroschlerosis
and malignant hypertension.
h
“Diabetes” includes both Type 1 and Type 2, as well as unclassiified cases.
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Changes in the future need for kidneys will be driven by several factors. One
underlying trend of interest is the incidence of new ESRD patients, which has
64
been stagnant in recent years at about 115,000. Only about one-third of these
newly diagnosed patients end up with a transplant or on the waiting list for a
transplant, and if that fraction increases (due, for example, to changes in waitlisting practice or to medical progress that improves the health of ESRD
patients, hence making them better candidates for a transplant), then it could
still be true that transplant need would increase as well. Since 2006, however,
there has been little increase in the rate at which patients are added to the
waiting list (as shown in figure 2).
There is considerable evidence of inconsistency in the process by which
ESRD patients are qualified for the transplant waiting list. One study found
that many newly diagnosed patients were not placed on the waiting list, despite
being healthier (in the sense of having a longer life expectancy on dialysis) than
65
those who were placed on the waiting list. The Agency for Healthcare
Research and Quality estimated that an “achievable benchmark” for transplant
66
eligibility was ten percentage points higher than the current national average.
A consistent evidence-based standard applied in every locality could help
achieve that goal. Thus, the current flow of patients onto the waiting list could
increase substantially, not because of an increase in the number of new ESRD
patients, but because of a change in the process of medical qualification.
VI
PROSPECTS FOR INCREASING THE NUMBER OF DONORS
Figure 5 shows trends in kidney donation since 1988. Several trends in figure
5 are worth noting. First, the number of deceased donors has exceeded the
number of living donors, except for the years 2000 through 2005. (The number
of deceased-donor kidneys, represented by the dashed line in figure 5, is about
twice as high as the number of deceased donors, because most deceased donors
yield two transplantable kidneys.) Second, overall donations were growing from
1988 to 2005, but have been static since then. That is the net result of somewhat
different trends in deceased and live donations. The number of deceased donors
64. Kam Kalantar-Zadeh, The Future of Dialysis in the U.S., RENAL & UROLOGY NEWS, Oct. 1,
2013, at S4. This generally stagnant rate of new ESRD patients masks significant differences across age
and ethnic groups. For example, in older populations (aged 60 and older), ESRD rates associated with
diabetes have declined for African Americans, Native Americans, and Hispanics but have increased for
whites aged 70 and older. Allan J. Collins et al., The State of Chronic Kidney Disease, ESRD, and
Morbidity and Mortality in the First Year of Dialysis, 4 CLINICAL J. AM. SOC’Y NEPHROLOGY S5, S6
(2009). In the age-group 20–39, however, diabetes incidence rates continue to rise for African
Americans and Native Americans. Id.
65. J.D. Schold et al., The Overlapping Risk Profile Between Dialysis Patients Listed and Not
Listed for Renal Transplantation, 8 AM. J. TRANSPLANTATION 58, 63 (2008) (linking various
characteristics of healthier patients to a disproportionately higher likelihood of not being listed).
66. AGENCY FOR HEALTHCARE RESEARCH & QUALITY, U.S. DEP’T OF HEALTH & HUMAN
SERVS., 2010 NATIONAL HEALTHCARE QUALITY REPORT 69 (2010), available at
http://www.ahrq.gov/research/findings/nhqrdr/nhqr10/pdf/nhqr10ch2.pdf.
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trended upward from 1988 to 2005, but has plateaued since then, rising only
slightly through 2012. The number of living kidney donors increased from 1988
to a high in 2003, then decreased through 2012. That downturn is surely a
matter of concern, but one for which we have no explanation.
67

Figure 5: Trends in kidney donors and kidneys donated from 1988
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In considering where to look for more kidneys, we begin with the basic
demographics: As shown in figure 6, all donors under age 18 are deceased, and
there are few donors living or deceased over age 64. In 2012, the peak agegroup for deceased donation was 18–34, whereas the peak age-group for living
donation was 35–49.

67. Kidney Donors by Donor Type, U.S. DEP’T HEALTH & HUMAN SERVS.,
http://optn.transplant.hrsa.gov/latestData/step2.asp? (choose “Donor” for category; select “Kidney”;
follow “All Donors by Donor Type” hyperlink; click “Add Field to Report” and select “Organs
Recovered”) (last updated Feb. 14, 2014).
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Figure 6: Kidney donors by age-group for 2012, living and deceased
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The fact that younger adults have the highest rate of deceased donation is
related to the criteria for kidney donation. The medical challenge for any
transplant team is to identify people who are about to die but are young enough
and healthy enough in relevant respects to provide disease-free, durable
kidneys that can be recovered in controlled circumstances (almost always in a
hospital) immediately after death. The standard criteria for a deceased kidney
donor is a patient who is declared brain-dead in a hospital while the heart is still
69
beating, who is aged sixty or less, and who does not suffer from any of a
70
number of identified medical conditions. (The medical criteria are somewhat
looser for patients under age fifty.) “Expanded” criteria for deceased kidney
donation includes otherwise healthy donors with brain death after age sixty,
although transplant centers reject kidneys from these donors about forty
71
percent of the time. There are also about 1000 cardiac-death donors each
68. Kidney Donors by Age and Donor Type, U.S. DEP’T HEALTH & HUMAN SERVS.,
http://optn.transplant.hrsa.gov/latestData/step2.asp? (choose “Donor” for category; select “Kidney”;
follow “All Donors by Donor Type” hyperlink; click “Add Field to Report”; and choose “Age (9
Items)”) (last updated Feb. 14, 2014).
69. D.W. McKeown et al., Management of the Heartbeating Brain-Dead Organ Donor, 108 BRIT. J.
ANESTHESIA i96, i96 (2012).
70. See Julio Pascual et al., A Systematic Review of Kidney Transplantation From Expanded
Criteria Donors, 52 AM. J. KIDNEY DISEASES 553, 553 (2008).
71. Id. at 558. OPTN and UNOS recently approved amendments to OPTN policy that replace the
definitions of standard-criteria and extended-criteria donor with the kidney donor profile index, a
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year—patients who are pronounced dead when their heart stops beating, rather
than as a result of cessation of brain function—but they too tend to be younger
72
patients who lack comorbidities.
The typical criteria that are applied to identifying suitable deceased donors
have the effect of disqualifying all but a small fraction of the 2.5 million people
who die each year. Table 3 provides some detail on this winnowing process for
2010, gathered by sorting the 2.5 million records from the National Vital
Statistics Multiple Cause Mortality Dataset according to particular fields in the
73
electronic records, beginning with age. We begin with the fact that almost twothirds of all deaths are of persons over seventy, such that the decedents are
almost always deemed medically unacceptable due to age alone. Of the
remainder, most die in uncontrolled settings out of the hospital, or in the
hospital from causes like cancer, diabetes, and renal disease that ordinarily are
disqualifying. In 2010 only about 9000 deaths were “eligible” by either the
standard criteria or expanded criteria, and in seventy percent of those cases the
kidneys were in fact donated. In addition, 928 others became donors after
cardiac death, which is uncommon because it is a difficult procedure—once the
74
heart stops beating, the kidneys deteriorate rapidly. Still, all hospitals that
accept Medicare now have donation-after-cardiac-death protocols, and it is an
75
expanding practice.
One lesson from these statistics is that even an organ consent-and-allocation
system with 100% compliance would have yielded only an additional 2751
donors, or roughly 5500 kidneys. This is not nearly enough to satisfy current
need, which is about 21,000 even counting just new cases per year—and is even
greater if the backlog is included.

formula designed to classify kidneys based on estimated years of function posttransplant. Transplant
professionals already have access to this formula and, according to OPTN, the change “does not affect
the decision-making process between an individual candidate and his or her transplant team regarding
kidney offers they would be willing to accept for a transplant.” OPTN/UNOS Board Approves
Significant Revisions to Deceased Donor Kidney Allocation Policy, U.S. DEP’T HEALTH & HUM.
SERVS. (June 25, 2013), http://optn.transplant.hrsa.gov/news/newsDetail.asp?id=1600.
72. See infra Table 3.
73. Vital Statistics Data Available Online, CTRS. FOR DISEASE CONTROL & PREVENTION,
http://www.cdc.gov/nchs/data_access/vitalstatsonline.htm (select “2010” under “Mortality Multiple
Cause Files”) [hereinafter Vital Statistics Data Available Online] (last visited Apr. 3, 2014); see generally
Sherry Murphy et al., Deaths: Final Data for 2010, NAT’L VITAL STATISTICS REPS., May 8, 2013.
74. See infra Table 3.
75. 42 C.F.R. § 486.322 (2006).
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Table 3: The winnowing process for deceased donors, 2010
Total deathsa
– Deaths > age 70a

2,468,435
(1,608,440)

= Deaths ≤ age 70a
– Deaths out of hospitala

859,995
(547,123)

= Deaths ≤ age 70 and in hospitala
– Medically unsuitable deaths*a

312,872
(176,451)

= Potentially eligible deathsb

136,421

– Deaths excluded due to other medical conditions or circulatory deathc (127,357)
d

= Eligible deaths (as reported by OPOs) **
– Not recovered (no consent, etc.)e

9,064
(2751)

= Kidney donors (SCD and ECD)f
+ Recovered kidney donors (DCD)f

6,313
928

= Total kidney donorsf
7241
Legend
OPO = Organ-procurement organization
SCD = Standard-criteria donor
ECD = Expanded-criteria donor
DCD = Donation after cardiac death
a. Original calculations are from the National Vital Statistics multiple cause mortality
dataset. Vital Statistics Data Available Online, supra note 73. See generally
MURPHY, supra note 7370.
b. Computed by subtracting “medically unsuitable deaths” from “Deaths <= 70 and in
hospital, as shown.”
c. Computed as the difference between “Potentially eligible deaths” and “eligible
deaths (as reported by OPOs).”
d. Table 4.2: Eligible Deaths Reported by U.S. OPOs, 2002–2011, SCI. REGISTRY
TRANSPLANT RECIPIENTS,
http://www.srtr.org/annual_Reports/2011/402_opo.aspx (last visited Sept. 20,
2013).
e. Computed as difference between “eligible deaths” and “recovered kidney donors”
f. Table 2.2: Deceased Donor Characteristics, 2002–2011, SCI. REGISTRY TRANSPLANT
RECIPIENTS, http://www.srtr.org/annual_Reports/2011/202_doncat-ecdc_dc.aspx
(last visited Sept. 20, 2013). Note that in some cases the kidneys are not used.
*Includes the following codes from the tenth revision of the International Statistical
Classification of Diseases and Related Health Problems (ICD-10): Certain infectious and
parasitic diseases (A00-B99); Malignant neoplasms (C00-C42, C45-C68, C73-C97); Diabetes
mellitus (E10-E14); Hypertension with renal insufficiency or renal failure (I12-I15); Renal
disease (N00-N29). Based on Akinlolu O. Ojo et al., A Practical Approach to Evaluate the
Potential Donor Pool and Trends in Cadaveric Kidney Donation, 67 TRANSPLANTATION 548
(1999).
**Resources: Glossary, U.S. DEP’T HEALTH & HUMAN SERVS.,
http://optn.transplant.hrsa.gov/resources/glossary.asp (last visited Feb. 21, 2014) (defining
“Eligible Death”).
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76. WISQA
ARS Fatal Inju
ury Reports, Na
ational and Reggional, 1981–19998, CTRS. FOR
R DISEASE
CONTROL & PREVENTION
R
, htttp://webappa.cdcc.gov/sasweb/nciipc/mortrate9.httml (generate reeport using
criteria “All intents,” “Motor vehicle, overalll,” and “1991”; then return an
nd generate seco
ond report
using criteria “Homicide and Legal interventtion,” “All injurry,” and “1991””) (last updateed Apr. 10,
RS Fatal Injury
y Reports, 1999–
–2010, CTRS. FO
OR DISEASE CO
ONTROL & PRE
EVENTION,
2013); WISQAR
http://webappa..cdc.gov/sasweb//ncipc/mortrate1
10_us.html (gen
nerate report ussing criteria “A
All intents,”
“Motor vehicle, overall,” and “2010”;
“
then return and generatte second reporrt using criteria ““Homicide
and Legal interv
vention,” “All in
njury,” and “201
10”) (last updateed Feb. 19, 20133).
77. Kidney
y Donors by Circumstance of
o Death, U.S.. DEP’T HEAL
LTH & HUMAN
N SERVS.,
http://optn.transplant.hrsa.gov/latestData/step2
2.asp? (choose “Donor” for ccategory; select “Kidney”;
follow “Deceassed Donors by Circumstance
C
off Death” hyperllink) (last updatted Feb. 14, 20114); Kidney
Donors
by
Cause
of
Death,
U.S.
U
DEP’T
HEALTH
&
HUMAN
SERVS.,
http://optn.transplant.hrsa.gov/latestData/step2
2.asp? (choose “Donor” for ccategory; select “Kidney”;
C
of Death” hyperlink) (lastt updated Feb. 114, 2014).
follow “Deceased Donors by Cause
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In sum, the prospect for substantial increases in deceased kidney donation is
dim. Although some suitable donors are lost due to refusal by transplant centers
or mismanagement, the most that could be gained from reducing those losses is
about 5000 additional kidneys per year. Medical science may progress to the
point of being able to salvage more organs from cardiac deaths and patients
whose age or medical history currently disqualifies them, but expanding on
those margins is likely to result in additional post-transplant problems. The
ready-at-hand solution is to expand the number of living donors, but in the face
of the recent decline in living donations, that will require a new approach.
All but 182 living donations in 2012 were directed to specific patients, in
most cases to members of the immediate family (figure 8). That pattern is not
surprising given that donation is a major medical procedure with some risks,
and that living donors are not compensated financially. Most are unwilling to
make such a considerable sacrifice for strangers. Indeed, the usual account of
living donation as altruistic perhaps creates the wrong impression. This is
largely a family matter.
Figure 8: Recipient relationship to live donor, 2012

78
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78. Kidney Donors by Donor Relation, U.S. DEP’T HEALTH & HUMAN SERVS.,
http://optn.transplant.hrsa.gov/latestData/step2.asp? (choose “Transplant” for category; select
“Kidney”; follow “Living Donor Transplants by Donor Relation” hyperlink) (last updated Feb. 14,
2014).
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If NOTA were amended to allow financial rewards to living donors that
went beyond the currently permitted compensation for lost wages, housing, and
travel, it seems reasonable to suppose that the result would be an increase in
living donations, both directed and undirected. The experience of Iran, as well
as evidence from the black market (not examples we wish to follow, to be sure)
79
provide support for this contention, as do studies of financial rewards in
80
related contexts, such as blood donation.
We do not want to suggest that financial rewards are the only way to
increase living donation. Perhaps with enough resources and creativity, an
effective marketing strategy could be devised that would better educate the
public about the need and the risks. Indeed, a campaign of that sort may well be
worthwhile even if a financial reward were introduced. Any major innovation
or combination of innovations in this area should be introduced on a limited
basis with an experimental mindset, because at present we can only speculate
about consequences.
VII
CONCLUSION
In this primer, we have presented a quantitative analysis of the kidney
shortage, with a tentative projection of future trends. That analysis provides
insights into the nature of the kidney shortage and illustrates why many
researchers and policy makers are now converging on inducements as a possible
solution.
The most important of these insights is the realization that improvements to
the deceased-donor consent-and-allocation system will not eradicate the kidney
shortage. As this primer demonstrates, current unmet need stands at about
21,000 kidneys per year and even a perfect deceased-donor consent-andallocation system would produce only an additional 2751 donors, or roughly
5500 kidneys, per year. Those additional kidneys would be welcome but not
nearly enough to satisfy current need, meaning that—barring a major
breakthrough in recovering organs from patients who are currently deemed
unsuitable—increasing donations from living donors is the only plausible means
to close the gap. We do not mean to suggest that efforts to increase rates of
deceased organ donation are not worthwhile or should be abandoned. Our

79. See Gary S. Becker & Julio Jorge Elías, Introducing Incentives in the Market for Live and
Cadaveric Organ Donations, J. ECON. PERSP., Summer 2007, at 3 (2007) (estimating the price at which
financial incentives would reduce the kidney waiting list). The Iranian model of compensated organ
donation has reportedly eliminated waiting lists, but created other problems, including a lack of donor
follow-up care. See, e.g., Ahad J. Ghods & Shekoufeh Savaj, Iranian Model of Paid and Regulated
Living-Unrelated Kidney Donation, 1 CLINICAL J. AM. SOC’Y NEPHROLOGY 1136, 1139 (2006).
80. See, e.g., Nicola Lacetera et al., Will There Be Blood? Incentives and Displacement Effects in
Pro-Social Behavior, 4 AM. ECON. J. ECON. POL’Y 186, 186 (2012) (presenting evidence from roughly
fourteen thousand American Red Cross blood drives and concluding that “economic incentives have a
positive effect on blood donations without increasing the fraction of donors who are ineligible to
donate”).
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point is simply that such efforts are likely to satisfy only about a quarter of
current unmet demand.
Living kidney donations will therefore have to make up the rest of the
needed supply of kidneys, leading to our second insight: Living kidney
donations are currently nearly all directed, usually to family members. Perhaps
with sufficient education and public outreach, the number of altruistic donors
could be increased. But it is not encouraging that there were only 182
nondirected donors in 2012, and that there is a recent downward trend in living
donations, despite current education and outreach efforts.
For all of these reasons, we believe the time is ripe to reconsider
inducements to kidney donation, and financial inducements in particular.
Needless to say, a system that provided financial rewards for living donors could
produce unsavory consequences, and would have to be carefully designed and
managed. But without such a system, the most likely version of the future is a
continuation of unnecessarily high rates of death and disability from kidney
failure.

